Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
FDA issues safety communication on reports of cancers around breast implants » 13:38
09/08/22
09/08
13:38
09/08/22
13:38
SIEN

Sientra

/

+

, ABBV

AbbVie

$140.12 /

+1.08 (+0.78%)

, JNJ

Johnson & Johnson

$164.45 /

+0.35 (+0.21%)

, ESTA

Establishment Labs

$64.13 /

+0.05 (+0.08%)

The U.S. Food and Drug…

The U.S. Food and Drug Administration is informing the public about reports of cancers, including squamous cell carcinoma, or SCC, and various lymphomas, in the scar tissue that forms around breast implants. The various lymphomas reported are not the same as the lymphomas described in previous FDA Communications as Breast Implant-Associated Anaplastic Large Cell Lymphoma, or BIA-ALCL, the agency stated. "The FDA learned about these reports through our continual postmarket review of breast implants and our ongoing collaboration with external stakeholders. After preliminary review of published literature as part of our ongoing monitoring of the safety of breast implants, the FDA is aware of less than 20 cases of SCC and less than 30 cases of various lymphomas in the capsule around the breast implant. As of September 1, 2022, the FDA has received 10 medical device reports about SCC related to breast implants and 12 MDRs about various lymphomas related to breast implants. The FDA recognizes the limitations of MDR data, including that reports do not necessarily represent unique cases. Reports submitted to the FDA are just one source the FDA uses to monitor the safety of medical devices, in addition to mandated postmarket studies, published literature, and real-world data from registries and claims databases. The FDA will continue to gather and review all available data from these sources to evaluate the occurrence of cancers in the capsule around breast implants," the agency stated. Breast implant makers include Sientra (SIEN), Abbvie's (ABBV) Allergan unit, Johnson & Johnson (JNJ) and Establishment Labs (ESTA). Reference Link

ShowHide Related Items >><<
SIEN Sientra
/

+

JNJ Johnson & Johnson
$164.45 /

+0.35 (+0.21%)

ESTA Establishment Labs
$64.13 /

+0.05 (+0.08%)

ABBV AbbVie
$140.12 /

+1.08 (+0.78%)

SIEN Sientra
/

+

05/13/22 Canaccord
Sientra price target lowered to $5 from $8 at Canaccord
04/14/22 Lake Street
Sientra initiated with a Buy at Lake Street
03/29/22 Canaccord
Sientra price target lowered to $8 from $10 at Canaccord
03/24/22 Maxim
Sientra price target lowered to $7 from $13 at Maxim
ABBV AbbVie
$140.12 /

+1.08 (+0.78%)

08/30/22 Piper Sandler
I-Mab price target lowered to $30 from $35 at Piper Sandler
08/24/22 Argus
AbbVie price target lowered to $155 from $165 at Argus
08/01/22 JPMorgan
AbbVie selloff Friday a buying opportunity, says JPMorgan
08/01/22 Barclays
AbbVie price target lowered to $160 from $174 at Barclays
JNJ Johnson & Johnson
$164.45 /

+0.35 (+0.21%)

07/21/22 UBS
Johnson & Johnson price target lowered to $180 from $185 at UBS
07/20/22 SVB Securities
Johnson & Johnson price target lowered to $194 from $200 at SVB Securities
07/20/22 Canaccord
Canaccord starts Arcellx at Buy, sees 'best-in-class' potential
07/20/22 Citi
Johnson & Johnson price target lowered to $201 from $205 at Citi
ESTA Establishment Labs
$64.13 /

+0.05 (+0.08%)

08/24/22 B. Riley
B. Riley starts Establishment Labs at Buy on 'significant growth' of implants
08/24/22 B. Riley
Establishment Labs initiated with a Buy at B. Riley
08/23/22 B. Riley
Establishment Labs initiated with a Buy at B. Riley
06/24/22 BTIG
Establishment Labs price target lowered to $90 from $105 at BTIG
SIEN Sientra
/

+

JNJ Johnson & Johnson
$164.45 /

+0.35 (+0.21%)

ESTA Establishment Labs
$64.13 /

+0.05 (+0.08%)

ABBV AbbVie
$140.12 /

+1.08 (+0.78%)

JNJ Johnson & Johnson
$164.45 /

+0.35 (+0.21%)

ABBV AbbVie
$140.12 /

+1.08 (+0.78%)

SIEN Sientra
/

+

JNJ Johnson & Johnson
$164.45 /

+0.35 (+0.21%)

ESTA Establishment Labs
$64.13 /

+0.05 (+0.08%)

ABBV AbbVie
$140.12 /

+1.08 (+0.78%)

JNJ Johnson & Johnson
$164.45 /

+0.35 (+0.21%)

ABBV AbbVie
$140.12 /

+1.08 (+0.78%)

Over a month ago
On The Fly
Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations » 10:07
08/24/22
08/24
10:07
08/24/22
10:07
ESTA

Establishment Labs

$64.95 /

+2.38 (+3.80%)

, ULCC

Frontier Group

$13.29 /

+0.555 (+4.36%)

, ANET

Arista Networks

$126.10 /

-1.04 (-0.82%)

, AVB

AvalonBay

$208.10 /

+1.36 (+0.66%)

, PLD

Prologis

$129.77 /

+1.23 (+0.96%)

, GTY

Getty Realty

$30.33 /

+0.32 (+1.07%)

, EPRT

Essential Properties Realty Trust

$23.47 /

+0.26 (+1.12%)

, SFL

SFL Corporation

$11.12 /

+0.27 (+2.49%)

, CDEV

Centennial Resource Development

$8.05 /

+0.305 (+3.94%)

, TWTR

Twitter

$39.60 /

-0.27 (-0.68%)

, XPEV

XPeng

$19.02 /

+0.295 (+1.58%)

, SNY

Sanofi

$40.22 /

-0.56 (-1.37%)

, MDT

Medtronic

$89.10 /

-1.11 (-1.23%)

, CPRX

Catalyst Pharmaceuticals

$13.23 /

-1.68 (-11.27%)

, VICI

VICI Properties

$33.86 /

+0.17 (+0.50%)

, ITW

Illinois Tool Works

$205.16 /

-0.26 (-0.13%)

Institutional investors…

ShowHide Related Items >><<
XPEV XPeng
$19.02 /

+0.295 (+1.58%)

VICI VICI Properties
$33.86 /

+0.17 (+0.50%)

ULCC Frontier Group
$13.29 /

+0.555 (+4.36%)

TWTR Twitter
$39.60 /

-0.27 (-0.68%)

SNY Sanofi
$40.22 /

-0.56 (-1.37%)

PLD Prologis
$129.77 /

+1.23 (+0.96%)

MDT Medtronic
$89.10 /

-1.11 (-1.23%)

ITW Illinois Tool Works
$205.16 /

-0.26 (-0.13%)

ESTA Establishment Labs
$64.95 /

+2.38 (+3.80%)

EPRT Essential Properties Realty Trust
$23.47 /

+0.26 (+1.12%)

CPRX Catalyst Pharmaceuticals
$13.23 /

-1.68 (-11.27%)

CDEV Centennial Resource Development
$8.05 /

+0.305 (+3.94%)

AVB AvalonBay
$208.10 /

+1.36 (+0.66%)

ANET Arista Networks
$126.10 /

-1.04 (-0.82%)

ESTA Establishment Labs
$64.95 /

+2.38 (+3.80%)

08/24/22 B. Riley
B. Riley starts Establishment Labs at Buy on 'significant growth' of implants
08/24/22 B. Riley
Establishment Labs initiated with a Buy at B. Riley
08/23/22 B. Riley
Establishment Labs initiated with a Buy at B. Riley
06/24/22 BTIG
Establishment Labs price target lowered to $90 from $105 at BTIG
ULCC Frontier Group
$13.29 /

+0.555 (+4.36%)

08/24/22 Morgan Stanley
Frontier Group resumed with an Overweight at Morgan Stanley
08/11/22 Barclays
Frontier Group reinstated with an Overweight at Barclays
08/10/22 Barclays
Frontier Group reinstated with an Overweight at Barclays
08/02/22 BofA
Frontier Group resumed with a Buy at BofA
ANET Arista Networks
$126.10 /

-1.04 (-0.82%)

08/24/22 Deutsche Bank
Arista Networks initiated with a Hold at Deutsche Bank
08/15/22 Citi
Cisco to trade lower due to valuation multiple compression, says Citi
08/02/22 Evercore ISI
Arista Networks price target raised to $145 from $135 at Evercore ISI
08/02/22 Cowen
Arista Networks price target raised to $163 from $154 at Cowen
AVB AvalonBay
$208.10 /

+1.36 (+0.66%)

08/24/22 Wolfe Research
AvalonBay upgraded to Outperform with $292 target at Wolfe Research
08/24/22 Wolfe Research
AvalonBay upgraded to Outperform from Peer Perform at Wolfe Research
08/11/22 Morgan Stanley
AvalonBay assumed with an Overweight at Morgan Stanley
07/20/22 Piper Sandler
AvalonBay price target lowered to $205 from $210 at Piper Sandler
PLD Prologis
$129.77 /

+1.23 (+0.96%)

08/24/22 Wolfe Research
Prologis upgraded to Outperform with $200 target at Wolfe Research
08/24/22 Wolfe Research
Prologis upgraded to Outperform from Peer Perform at Wolfe Research
07/28/22 Truist
Prologis price target lowered to $150 from $162 at Truist
GTY Getty Realty
$30.33 /

+0.32 (+1.07%)

08/24/22 BofA
Getty Realty upgraded on 'higher appetite' for outside growth at BofA
08/24/22 BofA
Getty Realty upgraded to Neutral from Underperform at BofA
05/10/22 JMP Securities
Getty Realty initiated with an Outperform at JMP Securities
01/20/22 BofA
Getty Realty downgraded to Underperform from Neutral at BofA
EPRT Essential Properties Realty Trust
$23.47 /

+0.26 (+1.12%)

08/24/22 BofA
Essential Properties upgraded to Buy after underperformance at BofA
08/24/22 BofA
Essential Properties Realty Trust upgraded to Buy from Neutral at BofA
06/22/22 Credit Suisse
Essential Properties Realty Trust assumed with a Neutral at Credit Suisse
05/25/22 Goldman Sachs
Essential Properties downgraded to Neutral from Buy at Goldman Sachs
SFL SFL Corporation
$11.12 /

+0.27 (+2.49%)

08/24/22 DNB Markets
SFL Corporation upgraded to Buy from Hold at DNB Markets
02/18/22 DNB Markets
SFL Corporation downgraded to Hold from Buy at DNB Markets
11/11/21 DNB Markets
SFL Corporation upgraded to Buy from Hold at DNB Markets
11/09/21 DNB Markets
SFL Corporation downgraded to Hold from Buy at DNB Markets
CDEV Centennial Resource Development
$8.05 /

+0.305 (+3.94%)

08/24/22 Truist
Truist upgrades Centennial Resource to Buy on 'transformational' Colgate merger
08/24/22 Truist
Centennial Resource Development upgraded to Buy from Hold at Truist
07/22/22 Piper Sandler
Centennial Resource price target lowered to $11 from $12 at Piper Sandler
07/20/22 MKM Partners
Centennial Resource Development assumed with a Buy at MKM Partners
TWTR Twitter
$39.60 /

-0.27 (-0.68%)

08/24/22 Gordon Haskett
Twitter whistleblower has no 'smoking gun,' says Gordon Haskett
08/24/22 Rosenblatt
Rosenblatt downgrades Twitter on risk of Musk using whistleblower suit
08/24/22 Rosenblatt
Twitter downgraded to Neutral from Buy at Rosenblatt
08/10/22 Gordon Haskett
Tesla sale shows Musk knows must come up with Twitter money, says Gordon Haskett
XPEV XPeng
$19.02 /

+0.295 (+1.58%)

08/24/22 Citi
XPeng price target lowered to $27.87 from $51.59 at Citi
08/24/22 Barclays
XPeng downgraded to Equal Weight on execution risks at Barclays
08/23/22 Barclays
XPeng downgraded to Equal Weight from Overweight at Barclays
08/03/22 Macquarie
XPeng downgraded to Neutral from Outperform at Macquarie
SNY Sanofi
$40.22 /

-0.56 (-1.37%)

08/24/22 Kepler Cheuvreux
Sanofi downgraded on Zantac litigation risk at Kepler Cheuvreux
08/24/22 Kepler Cheuvreux
Sanofi downgraded to Hold from Buy at Kepler Cheuvreux
08/19/22 Piper Sandler
Arvinas should be bought on recent weakness, says Piper Sandler
08/16/22 Cowen
DarioHealth price target lowered to $14 from $18 at Cowen
MDT Medtronic
$89.10 /

-1.11 (-1.23%)

08/24/22 Truist
Medtronic risk-reward balanced after mixed Q1, says Truist
08/24/22 Wells Fargo
Medtronic price target lowered to $96 from $104 at Wells Fargo
08/24/22 Raymond James
Medtronic downgraded to Market Perform from Outperform at Raymond James
08/23/22 Piper Sandler
Medtronic price target lowered to $90 from $100 at Piper Sandler
CPRX Catalyst Pharmaceuticals
$13.23 /

-1.68 (-11.27%)

08/24/22 Roth Capital
Catalyst Pharmaceuticals downgraded on valuation at Roth Capital
08/24/22 Roth Capital
Catalyst Pharmaceuticals downgraded to Neutral from Buy at Roth Capital
08/11/22 Truist
Catalyst Pharmaceuticals price target raised to $17 from $12 at Truist
08/11/22 H.C. Wainwright
Catalyst Pharmaceuticals price target raised to $18 from $12 at H.C. Wainwright
VICI VICI Properties
$33.86 /

+0.17 (+0.50%)

08/24/22 JMP Securities
VICI Properties initiated with an Outperform at JMP Securities
07/27/22 Ladenburg
VICI Properties price target raised to $36 from $33.50 at Ladenburg
07/20/22 Evercore ISI
VICI Properties resumed with an Outperform at Evercore ISI
07/20/22 Truist
VICI Properties price target raised to $40 from $35 at Truist
ITW Illinois Tool Works
$205.16 /

-0.26 (-0.13%)

08/24/22 BofA
Illinois Tool Works reinstated with a Neutral at BofA
08/15/22 Deutsche Bank
Illinois Tool Works downgraded to Sell at Deutsche Bank on valuation
08/15/22 Deutsche Bank
Illinois Tool Works downgraded to Sell from Hold at Deutsche Bank
08/03/22 Wells Fargo
Illinois Tool Works price target raised to $187 from $180 at Wells Fargo
XPEV XPeng
$19.02 /

+0.295 (+1.58%)

VICI VICI Properties
$33.86 /

+0.17 (+0.50%)

ULCC Frontier Group
$13.29 /

+0.555 (+4.36%)

TWTR Twitter
$39.60 /

-0.27 (-0.68%)

SNY Sanofi
$40.22 /

-0.56 (-1.37%)

PLD Prologis
$129.77 /

+1.23 (+0.96%)

MDT Medtronic
$89.10 /

-1.11 (-1.23%)

ITW Illinois Tool Works
$205.16 /

-0.26 (-0.13%)

GTY Getty Realty
$30.33 /

+0.32 (+1.07%)

ESTA Establishment Labs
$64.95 /

+2.38 (+3.80%)

EPRT Essential Properties Realty Trust
$23.47 /

+0.26 (+1.12%)

CPRX Catalyst Pharmaceuticals
$13.23 /

-1.68 (-11.27%)

CDEV Centennial Resource Development
$8.05 /

+0.305 (+3.94%)

AVB AvalonBay
$208.10 /

+1.36 (+0.66%)

ANET Arista Networks
$126.10 /

-1.04 (-0.82%)

  • 02
    Aug
  • 07
    Apr
  • 10
    Sep
XPEV XPeng
$19.02 /

+0.295 (+1.58%)

ULCC Frontier Group
$13.29 /

+0.555 (+4.36%)

TWTR Twitter
$39.60 /

-0.27 (-0.68%)

SNY Sanofi
$40.22 /

-0.56 (-1.37%)

PLD Prologis
$129.77 /

+1.23 (+0.96%)

AVB AvalonBay
$208.10 /

+1.36 (+0.66%)

XPEV XPeng
$19.02 /

+0.295 (+1.58%)

ULCC Frontier Group
$13.29 /

+0.555 (+4.36%)

TWTR Twitter
$39.60 /

-0.27 (-0.68%)

SNY Sanofi
$40.22 /

-0.56 (-1.37%)

PLD Prologis
$129.77 /

+1.23 (+0.96%)

MDT Medtronic
$89.10 /

-1.11 (-1.23%)

ITW Illinois Tool Works
$205.16 /

-0.26 (-0.13%)

CPRX Catalyst Pharmaceuticals
$13.23 /

-1.68 (-11.27%)

CDEV Centennial Resource Development
$8.05 /

+0.305 (+3.94%)

AVB AvalonBay
$208.10 /

+1.36 (+0.66%)

ANET Arista Networks
$126.10 /

-1.04 (-0.82%)

XPEV XPeng
$19.02 /

+0.295 (+1.58%)

TWTR Twitter
$39.60 /

-0.27 (-0.68%)

PLD Prologis
$129.77 /

+1.23 (+0.96%)

MDT Medtronic
$89.10 /

-1.11 (-1.23%)

CDEV Centennial Resource Development
$8.05 /

+0.305 (+3.94%)

ANET Arista Networks
$126.10 /

-1.04 (-0.82%)

Initiation
B. Riley starts Establishment Labs at Buy on 'significant growth' of implants » 06:58
08/24/22
08/24
06:58
08/24/22
06:58
ESTA

Establishment Labs

$62.65 /

+0.57 (+0.92%)

B. Riley analyst Neil…

B. Riley analyst Neil Chatterji initiated coverage of Establishment Labs with a Buy rating and $107 price target. The solid safety profile and natural aesthetic outcome for the company's Motiva breast implants will continue to "drive significant growth," Chatterji tells investors in a research note. Establishment Labs can almost triple its addressable market in breast augmentation Motiva launces in more geographies next year, Chatterji tells investors in a research note.

ShowHide Related Items >><<
ESTA Establishment Labs
$62.65 /

+0.57 (+0.92%)

ESTA Establishment Labs
$62.65 /

+0.57 (+0.92%)

08/24/22 B. Riley
Establishment Labs initiated with a Buy at B. Riley
08/23/22 B. Riley
Establishment Labs initiated with a Buy at B. Riley
06/24/22 BTIG
Establishment Labs price target lowered to $90 from $105 at BTIG
04/22/22 Cowen
Establishment Labs price target raised to $125 from $95 at Cowen
ESTA Establishment Labs
$62.65 /

+0.57 (+0.92%)

Initiation
Establishment Labs initiated with a Buy at B. Riley » 06:45
08/24/22
08/24
06:45
08/24/22
06:45
ESTA

Establishment Labs

$62.65 /

+0.57 (+0.92%)

B. Riley analyst Neil…

B. Riley analyst Neil Chatterji initiated coverage of Establishment Labs with a Buy rating and $107 price target.

ShowHide Related Items >><<
ESTA Establishment Labs
$62.65 /

+0.57 (+0.92%)

ESTA Establishment Labs
$62.65 /

+0.57 (+0.92%)

08/23/22 B. Riley
Establishment Labs initiated with a Buy at B. Riley
06/24/22 BTIG
Establishment Labs price target lowered to $90 from $105 at BTIG
04/22/22 Cowen
Establishment Labs price target raised to $125 from $95 at Cowen
04/22/22 BTIG
Establishment Labs price target raised to $110 from $95 at BTIG
ESTA Establishment Labs
$62.65 /

+0.57 (+0.92%)

Initiation
Establishment Labs initiated with a Buy at B. Riley » 21:12
08/23/22
08/23
21:12
08/23/22
21:12
ESTA

Establishment Labs

$62.65 /

+0.57 (+0.92%)

B. Riley initiated…

B. Riley initiated coverage of Establishment Labs with a Buy rating and $107 price target.

ShowHide Related Items >><<
ESTA Establishment Labs
$62.65 /

+0.57 (+0.92%)

ESTA Establishment Labs
$62.65 /

+0.57 (+0.92%)

06/24/22 BTIG
Establishment Labs price target lowered to $90 from $105 at BTIG
04/22/22 Cowen
Establishment Labs price target raised to $125 from $95 at Cowen
04/22/22 BTIG
Establishment Labs price target raised to $110 from $95 at BTIG
ESTA Establishment Labs
$62.65 /

+0.57 (+0.92%)

Hot Stocks
Establishment Labs announces completion of enrollment in Motiva US IDE study » 08:07
08/03/22
08/03
08:07
08/03/22
08:07
ESTA

Establishment Labs

$59.01 /

+0.46 (+0.79%)

Establishment Labs…

Establishment Labs Holdings announced it has completed enrollment in the Motiva US IDE clinical study. The final surgery in the primary reconstruction cohort was completed at Northwestern Memorial Hospital. The Augmentation cohort, which finished enrollment in August of 2019, will complete its third year of study follow-up this month. The Motiva US IDE study enrolled 827 patients at 32 centers in the US, Germany, and Sweden. The study is designed to assess the safety and effectiveness of Motiva breast implants in primary breast augmentation, primary breast reconstruction, and revision breast procedures. The study included 562 patients in the augmentation cohorts and 265 in the reconstructive cohorts. The study includes a Magnetic Resonance Imaging cohort of 250 patients who receive MRIs at years 1, 2, 3, 5, 7, and 10 to assess for silent rupture.

ShowHide Related Items >><<
ESTA Establishment Labs
$59.01 /

+0.46 (+0.79%)

ESTA Establishment Labs
$59.01 /

+0.46 (+0.79%)

06/24/22 BTIG
Establishment Labs price target lowered to $90 from $105 at BTIG
04/22/22 Cowen
Establishment Labs price target raised to $125 from $95 at Cowen
04/22/22 BTIG
Establishment Labs price target raised to $110 from $95 at BTIG
ESTA Establishment Labs
$59.01 /

+0.46 (+0.79%)

Over a quarter ago
Recommendations
Establishment Labs price target lowered to $90 from $105 at BTIG » 07:23
06/24/22
06/24
07:23
06/24/22
07:23
ESTA

Establishment Labs

$58.19 /

+2.13 (+3.80%)

BTIG analyst Marie…

BTIG analyst Marie Thibault lowered the firm's price target on Establishment Labs to $90 from $105 but keeps a Buy rating on the shares as part of a broader research note on medical technology and digital health names. The pain across the sector has been indiscriminate, and many companies that still offer healthy fundamentals, strong operating track records, and important product pipelines are losing a large portion of their market value, the analyst tells investors in a research note. Thibault adds that she prefers stocks with large cash balances, a line of sight to cash flow-breakeven, consistent quarterly outperformance, and multiples that compare well against pre-COVID levels.

ShowHide Related Items >><<
ESTA Establishment Labs
$58.19 /

+2.13 (+3.80%)

ESTA Establishment Labs
$58.19 /

+2.13 (+3.80%)

04/22/22 Cowen
Establishment Labs price target raised to $125 from $95 at Cowen
04/22/22 BTIG
Establishment Labs price target raised to $110 from $95 at BTIG
ESTA Establishment Labs
$58.19 /

+2.13 (+3.80%)

Earnings
Establishment Labs reports Q1 EPS (24c), consensus (38c) » 16:01
05/09/22
05/09
16:01
05/09/22
16:01
ESTA

Establishment Labs

$50.85 /

-10.59 (-17.24%)

Reports Q1 revenue…

Reports Q1 revenue $38.5M, consensus $35.26M. "The strong momentum in our business continued in the first quarter of 2022," said Juan Jose Chacon-Quiros, Chief Executive Officer. "First quarter revenue of $38.5 million was up 26.8% from the first quarter of 2021. With the positive underlying trends, we are maintaining our 2022 revenue guidance of $155 million to $165 million, which is an annual growth rate of 22% to 30%."

ShowHide Related Items >><<
ESTA Establishment Labs
$50.85 /

-10.59 (-17.24%)

ESTA Establishment Labs
$50.85 /

-10.59 (-17.24%)

04/22/22 Cowen
Establishment Labs price target raised to $125 from $95 at Cowen
04/22/22 BTIG
Establishment Labs price target raised to $110 from $95 at BTIG
06/23/21 BTIG
Establishment Labs price target raised to $88 from $82 at BTIG
ESTA Establishment Labs
$50.85 /

-10.59 (-17.24%)

Recommendations
Establishment Labs price target raised to $125 from $95 at Cowen » 07:46
04/22/22
04/22
07:46
04/22/22
07:46
ESTA

Establishment Labs

$79.18 /

-1.31 (-1.63%)

Cowen analyst Joshua…

Cowen analyst Joshua Jennings raised the firm's price target on Establishment Labs to $125 from $95 and keeps an Outperform rating on the shares. The analyst noted U.S. Motiva IDE trial 2-year results were presented at The Aesthetic Meeting in San Diego and he believes these data will revolutionize the global breast implant industry. Motiva's industry leading safety profile was decisively confirmed and the FDA approval pathway has been fully de-risked.

ShowHide Related Items >><<
ESTA Establishment Labs
$79.18 /

-1.31 (-1.63%)

ESTA Establishment Labs
$79.18 /

-1.31 (-1.63%)

04/22/22 BTIG
Establishment Labs price target raised to $110 from $95 at BTIG
06/23/21 BTIG
Establishment Labs price target raised to $88 from $82 at BTIG
ESTA Establishment Labs
$79.18 /

-1.31 (-1.63%)

Recommendations
Establishment Labs price target raised to $110 from $95 at BTIG » 07:28
04/22/22
04/22
07:28
04/22/22
07:28
ESTA

Establishment Labs

$79.18 /

-1.31 (-1.63%)

BTIG analyst Marie…

BTIG analyst Marie Thibault raised the firm's price target on Establishment Labs to $110 from $95 and keeps a Buy rating on the shares after the company's "impressive" interim data from its Motiva U.S. IDE study presented at The Aesthetic Meeting 2022. The total reoperation rate, including those not device-related, was 5.7%, and these results should de-risk FDA approval, which could come as soon as late first half of 2023, the analyst tells investors in a research note. Thibault adds that Motiva is "clearly an approvable implant", raising her valuation multiple from 11.5-times to 13-times her 12-24 month revenue estimate.

ShowHide Related Items >><<
ESTA Establishment Labs
$79.18 /

-1.31 (-1.63%)

ESTA Establishment Labs
$79.18 /

-1.31 (-1.63%)

06/23/21 BTIG
Establishment Labs price target raised to $88 from $82 at BTIG
ESTA Establishment Labs
$79.18 /

-1.31 (-1.63%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.